ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1440

Systemic Sclerosis in Pediatric Patients: An Epidemiological Study in a Large Insured Population in the US

Alexander Michel1, Marcela Rivera2, Tatsiana Vaitsiakhovich2, Simon Teal2 and Janethe Pena3, 1Epidemiology, Bayer Basel, Basel, Switzerland, 2Real World Evidence, Bayer AG, Berlin, Germany, 3Clinical Development, Bayer US LLC, Whippany, NJ

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Epidemiologic methods, pediatric rheumatology and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Pediatric Rheumatology – Clinical Poster I – ARHP

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Systemic sclerosis (SSc) is a very rare autoimmune disorder and only very few population-based epidemiological studies described its incidence and prevalence in children. In a nationwide, prospective hospital-based case-series from Finland, the incidence of SSc was 0.05 per 100,000 person-years in children aged 0–15 years based on 2 cases (Pelkonen et al. 1994). A field study in the UK by Herrick et al. (2010) that collected SSc cases from all secondary care physicians to whom childhood systemic sclerosis could be referred, reported an estimate of 0.027 cases per 100,00 person-years, based on 7 pediatric SSc cases. For North America, we could not identify any previous study on pediatric SSc epidemiology.

Methods:

We conducted a retrospective cohort study in the MarketScan Commercial Claims and Encounters Database of IBM Watson Health, a large US-based claims database containing data from over 50 million patients from over 150 large employers geographically distributed throughout the US that covers employees and their dependent family members. The database is frequently used for studies in the area of descriptive disease epidemiology. Study period was 01. Jan 2010 until 31. Dec 2015. Following manual review of electronic patient profiles from a sample of patients with SSc claims in MarketScan, cases of SSc were defined using the following minimal-criteria:

  • Raynauds Syndrome diagnosis and two SSc outpatient diagnosis (at least 30 days apart) or
  • Raynauds Syndrome diagnosis and one SSc inpatient diagnosis or
  • Three SSc outpatient diagnoses (two of these diagnosis should be at least 30 days apart) or
  • One SSc inpatient diagnosis plus one SSc outpatient diagnosis (on different dates)

Yearly incidence and prevalence estimates and 95% confidence intervals were calculated for each calendar year from 2010 until 2015. Incident cases were required to have no recorded claim of SSc any time before the entry date.

Results:

In the overall pediatric population (<18 years of age), yearly incidence estimates ranged from 0.29 (95% CI: 0.11–0.47) to 0.69 (95% CI: 0.43–0.95) cases per 100 000 person-years, based on 10-27 incident pediatric cases per year. Overall female to male ratio was 2.34 (75/32). Rates were highest in the 12-17 year age group (table 1).

Yearly prevalence ranged from 0.95 (95% CI: 0.78–1.16) to 1.20 (95% CI: 0.95–1.51) per 100 000 children, based on 77-165 prevalent cases per year.

Incidence rates per 100,000 person-years (95% CI)

Age (years)

2010

2011

2012

2013

2014

2015

<2

0.00 (–)

0.00 (–)

0.00 (–)

0.00 (–)

0.00 (–)

0.00 (–)

2–11

0.45 (0.17 – 0.72)

0.23 (0.05 – 0.41)

0.03 (0.00 – 0.10)

0.17 (0.00 – 0.34)

0.08 ( 0.00 – 0.20)

0.05 ( 0.00 – 0.15)

12–17

1.03 (0.54 – 1.52)

0.73 (0.35 – 1.11)

0.83 (0.45 – 1.22)

0.86 (0.43 – 1.30)

0.56 (0.21 – 0.91)

0.61 (0.21 – 1.00)

Conclusion:

Pediatric SSc is a very rare disorder. Our study based on a large pediatric population in the MarketScan claims-database in the US yielded higher incidence estimates than those observed previously in smaller studies conducted in Europe. The female/male disproportionality of SSc may be less pronounced in children than known from the adult population.


Disclosure: A. Michel, Bayer, 3; M. Rivera, Full time emplyee in Bayer AG, 3; T. Vaitsiakhovich, Bayer AG, 1, 3; S. Teal, Bayer AG, 1, 3; J. Pena, Bayer AG, 3.

To cite this abstract in AMA style:

Michel A, Rivera M, Vaitsiakhovich T, Teal S, Pena J. Systemic Sclerosis in Pediatric Patients: An Epidemiological Study in a Large Insured Population in the US [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/systemic-sclerosis-in-pediatric-patients-an-epidemiological-study-in-a-large-insured-population-in-the-us/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-sclerosis-in-pediatric-patients-an-epidemiological-study-in-a-large-insured-population-in-the-us/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology